FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05383014|
Recruitment Status : Not yet recruiting
First Posted : May 19, 2022
Last Update Posted : May 19, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
- To evaluate expression levels of CD135
- To assess the frequency of FLT3 gene mutations (ITD)
- association between FLT3-ITD mutation and CD135 expression and their correlation with hematological, immunophenotypic,and biochemical features.
|Condition or disease|
|Acute Myeloid Leukemia|
|Study Type :||Observational|
|Estimated Enrollment :||82 participants|
|Official Title:||Assessment of Association Between FLT3-ITD Gene Mutation and CD135 Expression and Their Correlation With Hematological,Immunophenotypic and Biochemical Characteristics in Acute Myeloid Leukemia.|
|Estimated Study Start Date :||June 1, 2022|
|Estimated Primary Completion Date :||June 1, 2024|
|Estimated Study Completion Date :||July 1, 2024|
- Correlation between FLT3 gene mutation and the expression of CD135 and their association with clinical outcome ,haematological, immunophenotypic , biochemical characteristics in the development and progression of AML. [ Time Frame: baseline ]analysis of association between FLT3 gene mutation and the level of expression of CD135 and analysis of clinical outcome , hematological,and immunophenotypic characteristics between patients with positive FLT3-ITD mutation and negatine patients
- To detect expression levels of CD135 and the frequency of FLT3- ITD gene mutations in the development and progression of AML -follow up of patient after induction of chemotherapy [ Time Frame: baseline ]
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
|Sampling Method:||Non-Probability Sample|
- Newly diagnosed Patients with acute myeloid leukemia (AML), who fullfill the WHO criteria.
- AML on top of myeloproliferative neoplasms or MDS.
- previously diagnosed AML on treatment
- Patients with any other type of malignant tumors
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05383014
|Contact: Shaimaa Abdelazeem Selim, Assist. lecturer||01006214247||Shaimaaselim95@gmail.com|
|Contact: Hanan Galal Abdel-Azeem, prof||01062226610||Hanangalal2000@yahoo.com|
|Study Director:||Marwa Mohammed Thabet, lecturer||clinical pathology department , Assiut University Hospital.|
|Study Director:||Alaa soliman Abd Elkadir, lecturer||clinical pathology department , Assiut University Hospital.|
|Responsible Party:||Shaimaa Abd Elazeem Saber Selim, Assist. lecturer, Assiut University|
|Other Study ID Numbers:||
FLT3-ITD and CD135 in AML
|First Posted:||May 19, 2022 Key Record Dates|
|Last Update Posted:||May 19, 2022|
|Last Verified:||May 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type